Pyxis Oncology, Inc. (PYXS) is a clinical-stage oncology company with no approved products and no material commercial revenue. Under a liquidation lens, the recovery posture is deeply negative. MFFAIS reports a cash liquidation value of approximately negative $22.7M, consistent with the balance sheet structure: total assets of $91.5M against total liabilities of $38.1M yields GAAP book equity of $53.4M, but the asset pool is dominated by items that take haircuts under liquidation assumptions. The largest haircutted asset classes are: (1) cash and restricted cash of $16.9M (recoverable at 100%), (2) short-term marketable securities of $51.4M (recoverable near par, assuming high-grade fixed income which is typical for clinical-stage biotechs, but subject to mark-to-market risk), and (3) PP&E net of $8.0M (50-70% recovery implies $4.0-5.6M). Operating lease right-of-use assets of $11.4M get zeroed under liquidation, while the corresponding operating lease liability of $18.7M remains at face value — a structural liability overhang. Total undiscounted lease obligations are $25.8M with payments extending beyond five years, creating a non-trivial liquidation burden. Intangible assets are carried at zero net book value ($2.9M gross, fully amortized), consistent with the 0% recovery assumption applied to intangibles. The retained deficit stands at $443.2M, reflecting cumulative losses since inception. Net loss for FY2025 was $79.6M on revenues of $13.9M (which appear to be collaboration/licensing revenues, not product sales). The deferred tax asset of $154.6M gross is subject to a full valuation allowance of $151.6M, yielding zero net DTA on the balance sheet — consistent with the liquidation lens which assigns 0% recovery to DTAs. The company carries $96.3M in NOL-related deferred tax assets (before valuation allowance), reflecting $390.9M in pre-tax federal NOL carryforwards and $218.2M in state NOLs — these have no liquidation value. No funded debt is present; the liability stack is composed of accounts payable ($10.9M), accrued liabilities ($8.6M), employee compensation liabilities ($3.3M), and operating lease liabilities ($18.7M). The filing discusses China withholding tax of $1.3M paid in 2025 (not present in prior year), indicating a new foreign tax obligation associated with a collaboration arrangement, but the underlying collaboration revenue and associated IP licensing terms are discussed in MD&A and footnotes without a dedicated balance-sheet XBRL tag for the deferred revenue or collaboration receivable separately. The company's 10-K does not separately tag deferred collaboration revenue in XBRL, which limits balance-sheet granularity. Since the prior filing provided (10-Q for Q3 2025) does not contain balance sheet data for direct comparison, period-over-period balance sheet change analysis is not available from the provided inputs.
▼ Community Notes